~98% of the human genome is composed of non-protein coding regions. This portion of the genome, known as the 'dark genome,' is dynamically active, generating thousands of therapeutically unexplored long non-coding RNAs (lncRNAs).
LncRNAs regulate disease-associated gene pathways and proteins in response to the environment, triggering a disease-associated cell state.
Identify circulating dark genome biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice.
Our platform is powerful and versatile, but through partnerships we believe we can do more and help thousands of patients without a current therapeutic option. Partnering with biopharma companies with a given disease or modality expertise is essential to fulfill our mission. Each disease is a unique universe, and each target may require a different approach.
If you are interested in partnering, please: